The luteinizing hormone/choriogonadotropin receptor (LHCGR) is the primary gateway through which the pituitary communicates its ovulatory signal to the ovary. When the pituitary releases a surge of LH, it binds LHCGR on theca cells and mature granulosa cells, triggering steroidogenesis, follicle rupture, and corpus luteum formation. In males, the same receptor on Leydig cells drives testosterone production. rs13405728 is an intronic variant deep within LHCGR¹¹ intronic variant deep within LHCGR
Located at c.161+4491, meaning 4,491 nucleotides into the first intron of the coding sequence; its exact regulatory effect is still being characterized that was identified as one of the strongest PCOS susceptibility signals in the first genome-wide association study of PCOS — and remains one of the most replicated PCOS loci in Asian populations.

The Mechanism

The A allele at rs13405728 is enriched in PCOS cases and tracks with a hormonal phenotype characterized by elevated androgens, higher LH/FSH ratios, and metabolic dysregulation. Carriers of the AA genotype showed significantly elevated total testosterone, triglycerides, and LDL cholesterol compared to those with the AG or GG genotype²² Carriers of the AA genotype showed significantly elevated total testosterone, triglycerides, and LDL cholesterol compared to those with the AG or GG genotype
Pairwise comparisons in 151 PCOS cases and 99 controls from the Hui Chinese cohort. The protective G allele is present in roughly 7% of Europeans, 27% of East Asians, and 28% of Africans, making this one of the most population-stratified PCOS loci known — a difference that likely explains why PCOS prevalence and phenotype show significant ethnic variation.

The molecular mechanism is not yet established at the protein level, as this is an intronic variant with no direct amino acid consequence. A 2021 three-dimensional genome mapping study identified STON1 and FSHR — not LHCGR itself — as the most likely functional targets of this locus³³ A 2021 three-dimensional genome mapping study identified STON1 and FSHR — not LHCGR itself — as the most likely functional targets of this locus
Hi-C chromatin interaction data showed rs13405728 in spatial contact with STON1 promoter elements and the FSHR regulatory region; LHCGR expression was not differentially expressed in PCOS ovarian tissue despite proximity. STON1 is implicated in adipocyte metabolism; FSHR modulates follicle immune signaling. This finding reframes the locus as a regulatory hub for the broader gonadotropin signaling neighborhood rather than a simple LHCGR coding effect.

The Evidence

The original GWAS by Chen et al.⁴⁴ The original GWAS by Chen et al.
Genome-wide association study identifies susceptibility loci for polycystic ovary syndrome on chromosome 2p16.3, 2p21 and 9q33.3. Nature Genetics, 2011 analyzed three cohorts totalling 4,082 PCOS cases and 6,687 controls from Han Chinese women. rs13405728 emerged as the top hit at the 2p16.3 locus with a combined OR of 0.71 (meaning the G allele is protective) and P=7.55×10⁻²¹ — one of the strongest GWAS signals ever observed for a PCOS locus.

A 2018 meta-analysis pooling 14 case-control studies (11,738 PCOS cases, 35,329 controls)⁵⁵ A 2018 meta-analysis pooling 14 case-control studies (11,738 PCOS cases, 35,329 controls)
Association of luteinizing hormone/choriogonadotropin receptor gene polymorphisms with polycystic ovary syndrome risk. Gynecological Endocrinology, 2018 confirmed the association in Asian populations across multiple genetic models (G vs A: OR=0.735, 95% CI=0.699–0.773; GG vs AA+AG: OR=0.578, P<.001). Importantly, rs13405728 was not significantly associated with PCOS in Caucasian populations — a finding consistent with the low minor allele frequency (~7%) in Europeans, which limits statistical power for detection.

A study of Hui Chinese women found the AA genotype (homozygous risk) present in 65.5% of PCOS cases vs 49.5% of controls⁶⁶ found the AA genotype (homozygous risk) present in 65.5% of PCOS cases vs 49.5% of controls
Association Study between Polycystic Ovarian Syndrome and the Susceptibility Genes Polymorphisms in Hui Chinese Women. PLOS ONE, 2015, with the A allele carrying an OR of 1.729 (95% CI 1.149–2.603) for PCOS diagnosis. The AA genotype specifically showed elevations in total testosterone (69.5 vs 62.2 ng/dL, P=0.014), triglycerides (1.46 vs 1.38 mmol/L, P=0.038), and LDL cholesterol (2.71 vs 2.38 mmol/L, P=0.023).

In IVF outcomes, a 2019 case-control study of PCOS patients undergoing IVF-ET⁷⁷ a 2019 case-control study of PCOS patients undergoing IVF-ET
Association of Rs13405728, Rs12478601, and Rs2479106 SNPs and in vitro fertilization and embryo transfer efficacy in patients with polycystic ovarian syndrome. Medicine, 2019 found that the TT genotype (equivalent to AA on the plus strand) was associated with poor treatment outcomes, including lower clinical gestation rates compared to CT/CC carriers.

The rs13405728 locus also extends beyond reproductive conditions. A study of Han Chinese women⁸⁸ A study of Han Chinese women
Variants in DENND1A and LHCGR are associated with endometrioid adenocarcinoma. Gynecologic Oncology, 2012 found that allele A conferred risk for endometrioid adenocarcinoma (endometrial cancer), connecting the PCOS androgen-signaling pathway to endometrial cancer susceptibility — a link consistent with the established epidemiological association between PCOS and endometrial cancer risk.

Practical Implications

For women carrying the AA genotype, the actionable considerations center on early clinical evaluation for PCOS features, monitoring of androgens and metabolic markers, and awareness of IVF implications. The A allele is the ancestral common allele in all populations — the AA genotype represents the absence of the protective G allele rather than a rare mutation. This contextualizes the risk appropriately: this genotype does not guarantee PCOS, but confers a meaningful increase in susceptibility, especially in East Asian and South Asian individuals where the G allele is substantially more common (27%) than in Europeans (7%).

For individuals of East Asian ancestry, where the G allele frequency (~27%) means the AG genotype is relatively common, heterozygosity provides partial protection worth knowing about. In European individuals, the AG genotype is uncommon enough (~13%) that finding it represents a genuinely meaningful deviation from the background risk.

Interactions

DENND1A rs2479106: The most clinically important compound interaction with this SNP. DENND1A encodes a regulator of androgen biosynthesis in theca cells, and rs2479106 is the other major PCOS GWAS locus. Both were identified in the same original GWAS⁹⁹ Both were identified in the same original GWAS
Chen et al. 2011, Nature Genetics and the same IVF study found that both the AA genotype at rs13405728 AND the AG/GG genotype at rs2479106 independently predicted poor IVF-ET outcomes. When both risk genotypes are present, two distinct PCOS-promoting pathways converge: DENND1A rs2479106 drives abnormal androgen production in theca cells via the DENND1A-CYP17A1 axis, while the rs13405728 locus affects gonadotropin receptor signaling and LH sensitivity. A person carrying both risk genotypes faces a dual-pathway androgen excess phenotype — one from dysregulated biosynthesis, one from altered receptor signaling — which may produce a more severe or treatment-resistant PCOS presentation than either variant alone. The recommended approach for this combination would integrate both biosynthetic pathway support (inositol supplementation targeting DENND1A-linked insulin-androgen coupling) and gonadotropin monitoring (LH/FSH ratio tracking relevant to the LHCGR locus).

LHCGR rs2293275 (N312S): This coding-variant in the same gene (LHCGR Asn312Ser) has documented effects on IVF outcomes and ovarian stimulation response. Carrying both an intronic susceptibility variant (rs13405728) and the coding N312S variant may compound LH receptor signaling alterations, though direct interaction studies between these two specific LHCGR variants are not yet published.

FSHR rs6166 (N680S): The FSH receptor N680S variant governs ovarian response to FSH stimulation and is on the same chromosome (2p) near the LHCGR locus. Both LHCGR and FSHR variants operate in the same gonadotropin signaling neighborhood; combined receptor sensitivity profiles from both genes may define distinct IVF pharmacogenetic subgroups.

NTRK2 encodes TrkB (tropomyosin receptor kinase B), the primary receptor for brain-derived neurotrophic factor (BDNF)¹¹ brain-derived neurotrophic factor (BDNF)
A protein that promotes neuronal survival, growth, and synaptic plasticity — often called the brain's "fertilizer" because of its role in keeping neurons healthy and connected. When BDNF binds TrkB, it triggers intracellular signaling cascades that determine whether neurons form new connections, survive cellular stress, or respond to antidepressants. NTRK2 is consistently implicated in depression genetics — not just as a risk gene, but as a mechanistic hub that explains why some people respond to certain treatments and others don't.

The rs1387923 variant sits in the 3' untranslated region (3' UTR) of the NTRK2 gene — a region that controls mRNA stability and translation efficiency²² mRNA stability and translation efficiency
The 3' UTR contains binding sites for microRNAs and RNA-binding proteins that regulate how much TrkB protein gets made from each mRNA copy. Rather than changing the TrkB protein structure, this variant likely alters how much receptor is produced in neurons, particularly during stress or when antidepressants engage the BDNF pathway.

The Mechanism

TrkB receptor density matters. When BDNF is released from active neurons, it needs sufficient TrkB on the target cell surface to trigger synaptic plasticity³³ synaptic plasticity
The ability of synapses to strengthen or weaken over time, which underlies learning, memory, and mood regulation. A 3' UTR variant affecting mRNA stability could reduce TrkB surface expression in a dose-dependent manner — so G-allele homozygotes may have chronically lower TrkB availability. This would blunt the neurotrophic response to BDNF, impair hippocampal neurogenesis (which is disrupted in depression), and reduce the brain's ability to reorganize after stress.

Critically, many antidepressants — including SSRIs, SNRIs, ketamine, and even lithium — exert part of their effect by upregulating BDNF and potentiating TrkB signaling⁴⁴ upregulating BDNF and potentiating TrkB signaling
These drugs don't just adjust neurotransmitter levels; growing evidence shows they directly enhance TrkB sensitivity and downstream plasticity signaling. A variant reducing TrkB expression may therefore blunt the response to these treatments — a mechanistic basis for treatment resistance.

The Evidence

The strongest evidence for rs1387923 comes from a multicenter prospective study of Han Chinese patients with major depressive disorder⁵⁵ multicenter prospective study of Han Chinese patients with major depressive disorder
Li et al. Journal of Psychiatric Research, 2013, n=948 MDD patients followed longitudinally. Investigators found that the rs1387923+rs1565445 two-SNP haplotype conferred a 1.41-fold increased risk of treatment-resistant depression (p = 0.0014). When BDNF rs6265 was added to form a four-locus model, gene-gene interaction was the strongest predictor of treatment resistance in the entire cohort.

In bipolar disorder, a 2007 pharmacogenetics study⁶⁶ 2007 pharmacogenetics study
Bremer et al. Molecular Diagnostics and Therapeutics, n=184 lithium responders vs. non-responders found significant interactions between rs1387923, rs1565445, and lithium response, particularly when combined with suicidal ideation as a comorbidity. The same NTRK2 variants also appeared in a 2013 bipolar I study⁷⁷ 2013 bipolar I study
Wang et al. Journal of Molecular Neuroscience, n=579 examining mood stabilizer (lithium and valproate) response.

A 2020 Polish case-control study⁸⁸ 2020 Polish case-control study
Suchanek-Raif et al. Disease Markers, n=192 schizophrenia patients, 264 controls found that the G/G genotype at rs1387923 was specifically associated with increased schizophrenia risk in men, while A/A homozygosity was protective. This sex-specific pattern highlights that TrkB signaling interacts with sex hormones in determining psychiatric vulnerability.

A pathway-level perspective comes from a UK population-based imaging study⁹⁹ UK population-based imaging study
Juhasz et al. Biological Psychiatry, 2011, n>2,000 examining nine variants across the CREB1-BDNF-NTRK2 signaling axis. NTRK2 variants amplified the effect of childhood adversity on lifetime depression risk, consistent with the gene's role as a plasticity gate: in people with adequate TrkB signaling, early-life stress may be buffered; with reduced TrkB function, the same stress produces lasting neurobiological changes.

Practical Actions

For those carrying the G allele — particularly G/G homozygotes — the actionable insight is that your BDNF pathway may have a reduced amplification gain, meaning both therapeutic interventions and lifestyle factors that work through BDNF are especially important to maximize. Aerobic exercise is the most consistently effective strategy for increasing both BDNF secretion and TrkB expression in humans, with neuroimaging studies showing hippocampal volume increases that parallel BDNF upregulation. For those who haven't responded to first-line antidepressants, the evidence linking this variant to treatment-resistant depression supports proactive escalation to augmentation strategies — particularly lithium augmentation, where NTRK2 genotype has shown predictive value in pharmacogenetic studies.

Ketamine and ketamine-based treatments (esketamine) work through rapid BDNF/TrkB pathway activation and represent a mechanistically rational escalation option for G/G carriers with treatment-resistant depression.

Interactions

The most important interaction is with BDNF rs6265 (Val66Met). Studies consistently find that rs1387923 risk genotypes combine with BDNF rs6265 to produce gene-gene interactions stronger than either variant alone. In the Li et al. 2013 cohort, the four-locus model (rs1387923 + rs1565445 + rs2769605 + BDNF rs6265) was the key predictor of treatment-resistant depression — suggesting the entire BDNF→TrkB signaling axis needs to be considered together.

The rs1565445 variant is in linkage disequilibrium with rs1387923 and is typically analyzed as part of the same haplotype block. Carriers who also carry rs2769605 represent a higher-risk subgroup with compounded NTRK2 signaling reduction.

Urinary tract infections (UTIs) are among the most common bacterial infections in humans, affecting roughly 50% of women at least once in their lifetime and frequently recurring in a subset genetically predisposed to mucosal colonization by uropathogenic E. coli. While immune signaling genes like TLR4 have long been linked to UTI susceptibility, a 2017 genome-wide association study identified a second independent locus — an intronic variant in FRMD5¹¹ FRMD5
FERM domain-containing protein 5, a cytoskeletal scaffolding protein expressed at epithelial cell junctions — pointing to uroepithelial barrier integrity as a distinct axis of innate UTI defense.

The Mechanism

FRMD5 is a member of the FERM (Four-point-one, Ezrin, Radixin, Moesin) domain superfamily — a class of proteins that physically link the actin cytoskeleton to transmembrane adhesion molecules and junction complexes. FRMD5 localizes to cell adherens junctions and interacts with p120-catenin²² FRMD5 localizes to cell adherens junctions and interacts with p120-catenin
p120-catenin is a key regulator of E-cadherin stability and epithelial barrier function at cell-cell contacts. It also binds directly to the cytoplasmic tail of integrin β5 and inhibits ROCK1-mediated myosin phosphorylation³³ binds directly to the cytoplasmic tail of integrin β5 and inhibits ROCK1-mediated myosin phosphorylation
ROCK1 drives stress fiber contraction; FRMD5 acts as a brake on this pathway to stabilize cell-matrix adhesion, promoting tight cell-surface attachment over migratory, loosely adherent states.

The rs146906133 variant is intronic and does not alter the FRMD5 protein sequence. It likely acts as a regulatory variant affecting FRMD5 transcription or splicing in uroepithelial tissue, although the exact mechanism has not yet been functionally characterized. The plausible biological model is that altered FRMD5 expression changes the structural stiffness of the uroepithelial cell layer — either making it more or less permeable to bacterial attachment and the cytoskeletal remodeling that uropathogenic E. coli exploit during invasion. The rare C allele may increase FRMD5 expression in bladder epithelium, reinforcing tight junction stability and reducing the cytoskeletal rearrangements that allow bacteria to access and persist within uroepithelial cells.

FRMD5 has also been identified as upregulated during Plasmodium berghei infection⁴⁴ upregulated during Plasmodium berghei infection
a rodent malaria parasite, in a serum proteomics study, consistent with the idea that FRMD5 participates in the cell-to-cell adhesion dynamics exploited by intracellular and epithelium-invading pathogens more broadly.

The Evidence

The association at rs146906133 was discovered by Tian et al. in a 2017 Nature Communications genome-wide study⁵⁵ Tian et al. in a 2017 Nature Communications genome-wide study
23andMe research group, analyzing 23 infection phenotypes in over 200,000 individuals of European ancestry. The study identified 59 genome-wide significant associations across all infections, of which the FRMD5 locus was the second independent hit for UTI frequency (the first being a locus near the TLR4 pathway). The T allele (reference, common in >98% of Europeans) was associated with higher self-reported UTI frequency (beta = 0.38, 95% CI 0.32–0.45, p = 2.02×10⁻⁸). Importantly, this study used UTI frequency as a quantitative phenotype, so the beta represents the change in standardized UTI frequency score per allele copy.

The evidence level is emerging: the GWAS signal is genome-wide significant, but the study was observational and self-reported, functional validation of the FRMD5 intronic variant in uroepithelial cells has not been published, and no independent replication cohort has been reported specifically for rs146906133. The biological plausibility is high given FRMD5's established roles in epithelial adhesion, but the mechanistic link to UTI remains inferred.

The C allele is notably more common in East Asian populations (~5.8% allele frequency) than in Europeans (~0.75%) or Africans (<0.1%). Whether the C allele confers the same magnitude of protection in non-European populations has not been tested.

Practical Implications

For the rare carriers of the protective C allele (approximately 1.5% of Europeans carry at least one copy), the genetic data suggest a meaningfully lower biological susceptibility to recurrent UTIs — not immunity, but a measurable difference in how readily uropathogenic bacteria establish persistent mucosal infection. This likely reflects more resilient uroepithelial barrier function rather than any difference in classical immune signaling.

Given that the mechanism involves epithelial structural integrity, factors that further support mucosal barrier health — particularly adequate hydration to maintain urinary flow, and probiotic approaches that compete with uropathogenic colonizers at the vaginal and periurethral mucosa — may complement the genetic protection.

Conversely, the TT genotype (the common reference state) simply reflects the normal population-level baseline susceptibility to UTIs. This genotype alone does not predict recurrent UTIs — many other genetic and behavioral factors (sexual activity frequency, contraceptive choice, anatomical features, other UTI-susceptibility variants) shape overall UTI burden.

Interactions

The FRMD5 locus (rs146906133) and the TLR4 signaling locus represent two independent genetic axes of UTI susceptibility: barrier integrity versus innate immune signaling, respectively. Variants in TLR4 (rs4986790, rs4986791), the secretor status gene FUT2 (which governs whether uropathogens can adhere to certain blood group antigen substrates on the uroepithelium), and complement system genes are all relevant to overall UTI susceptibility and represent distinct pathways from FRMD5's cell adhesion role.

Your kidneys perform a quiet daily miracle: filtering 7–8 grams of uric acid from your blood, then reabsorbing roughly 90% of it back before it can reach the urine. The protein that does most of this recapture is URAT1 (Urate Transporter 1)¹¹ URAT1 (Urate Transporter 1)
Encoded by SLC22A12. An antiporter on the apical membrane of proximal tubule cells that exchanges urate for organic anions (lactate, nicotinate, pyrazinoate), rescuing filtered uric acid back into the bloodstream. Without URAT1, most uric acid would simply spill into the urine. The R90H variant (rs147647315) introduces a histidine at position 90 of the URAT1 protein in place of the usual arginine, destabilising the transporter and impairing its urate-reabsorption function. The result is persistently low serum uric acid — a condition called renal hypouricemia²² renal hypouricemia
A phenotype defined by serum uric acid below 2 mg/dL caused by impaired renal reabsorption; most carriers are asymptomatic but can develop exercise-induced acute kidney injury during vigorous or prolonged physical activity type 1 (RHUC1).

Unlike the more studied W258X variant (rs121907892) that predominates in East Asian populations, R90H (rs147647315) is the primary SLC22A12 loss-of-function allele in populations of African ancestry. A genome-wide association study³³ genome-wide association study
Chen G et al. Refining genome-wide associated loci for serum uric acid in individuals with African ancestry. Hum Mol Genet, 2020 in more than 9,000 continental Africans and African Americans identified rs147647315 as the strongest signal at the SLC22A12 locus (P = 6.65 × 10⁻²⁵) and the sole causal variant at that locus when functional annotation was applied to kidney tissue.

The Mechanism

The arginine at position 90 normally forms a stable hydrogen bond with glutamine 93, helping to anchor that region of the protein. When histidine replaces arginine, the bond lengthens from 2.3 Å (wild-type) to 3.1 Å — at the edge of the hydrogen-bond distance range. This weakened interaction destabilises the local protein domain and likely impairs the folding or membrane integration of URAT1. Structural modelling⁴⁴ Structural modelling
Zhou Z et al. Renal hypouricemia caused by novel compound heterozygous mutations in the SLC22A12 gene: a case report with literature review. BMC Med Genet, 2018 of compound heterozygous patients carrying R90H alongside another truncating mutation confirmed that the resulting protein is functionally impaired, producing the hallmark biochemical phenotype: dramatically elevated fractional excretion of uric acid and very low serum urate.

The broader class of nonfunctional URAT1 variants — of which R90H is one — produces protein that is not properly membrane-localised. Without stable insertion into the apical tubule membrane, URAT1 cannot exchange urate and the kidney's urate recapture capacity is sharply reduced.

The Evidence

African ancestry GWAS: Chen et al. (2020)⁵⁵ Chen et al. (2020)
Chen G et al. Refining genome-wide associated loci for serum uric acid in individuals with African ancestry. Hum Mol Genet, 2020 is the pivotal study for rs147647315 specifically. Among 9,133 participants of African descent, rs147647315 was identified as both the strongest statistical association at the SLC22A12 locus (P = 6.65 × 10⁻²⁵) and the sole functionally prioritised causal variant at that locus, with kidney tissue identified as the relevant biological context. This work established that the A allele of rs147647315 independently drives the serum uric acid-lowering signal at SLC22A12 in this ancestry group.

Phenotypic characterisation of nonfunctional URAT1: Sakiyama et al. (2016)⁶⁶ Sakiyama et al. (2016)
Sakiyama M et al. The effects of URAT1/SLC22A12 nonfunctional variants, R90H and W258X, on serum uric acid levels and gout/hyperuricemia progression. Sci Rep, 2016 studied 1,993 gout patients and 2,499 health examinees in Japan. Nonfunctional URAT1 variants (R90H and W258X combined) were absent in every single gout case. Among health examinees, males carrying one nonfunctional allele had serum uric acid 2.19 mg/dL lower than those without; females showed 1.08 mg/dL lower levels. Two nonfunctional alleles reduced urate by 5.42 mg/dL (males) and 3.89 mg/dL (females) — a sex-dependent dosage effect (interaction P = 1.5 × 10⁻¹²).

Toyoda et al. (2021)⁷⁷ Toyoda et al. (2021)
Toyoda Y et al. Substantial anti-gout effect conferred by common and rare dysfunctional variants of URAT1/SLC22A12. Rheumatology (Oxford), 2021 quantified the anti-gout protection at a reciprocal OR of 29.6 (P = 7.66 × 10⁻⁸) across all dysfunctional URAT1 variants combined, confirming that functional loss of URAT1 — regardless of the specific mutation — provides among the strongest single-variant gout protection documented in humans.

Large-scale Japanese epidemiology: Kawamura et al. (2021)⁸⁸ Kawamura et al. (2021)
Kawamura Y et al. A proposal for practical diagnosis of renal hypouricemia. Biomedicines, 2021 studied 30,685 Japanese health examinees and confirmed that nonfunctional URAT1 variants (including R90H) significantly increased fractional excretion of uric acid (P = 1.27 × 10⁻⁴⁶ in males) and decreased serum uric acid (P = 2.47 × 10⁻⁵³ in males). The study proposed that FEUA and SUA biomarkers together can guide clinical suspicion of URAT1 variant burden before genetic testing.

Exercise-induced AKI risk: Among individuals with complete or near-complete URAT1 loss of function (homozygous or compound heterozygous for nonfunctional variants), vigorous physical activity can trigger exercise-induced acute kidney injury (EIAKI)⁹⁹ acute kidney injury (EIAKI)
AKI presenting hours after intense exercise with flank pain, haematuria, and oliguria; believed to result from uric acid surges in the tubular lumen exceeding solubility when renal excretion is maximal and urine is concentrated. Kawamura et al. (2021)¹⁰¹⁰ Kawamura et al. (2021) and multiple case series confirm that homozygous or compound heterozygous URAT1 loss-of-function — including R90H paired with W258X or another nonfunctional allele — accounts for most clinically documented EIAKI.

Practical Actions

For heterozygous carriers (AG), the picture is straightforward: moderately lower serum uric acid and strong protection against gout. No specific intervention is required beyond awareness. Exercise is safe with normal hydration precautions.

For the extremely rare homozygous carrier (AA), or compound heterozygous carriers (one A allele at this locus plus a nonfunctional allele at another URAT1 position), the full loss-of-function phenotype produces clinically significant hypouricemia with EIAKI risk. These individuals should be followed by a nephrologist and should understand the pre-exercise hydration and urinary alkalinisation protocols that reduce tubular urate crystal formation risk.

Interactions

rs121907892 (SLC22A12 W258X): The W258X truncating variant is the most common nonfunctional URAT1 allele in East Asian populations. Compound heterozygosity for R90H and W258X — one copy of each nonfunctional allele — produces the same near-total URAT1 loss-of-function as homozygosity for either variant alone. EIAKI risk is highest in this compound heterozygous state. Reports from Japanese patients include R90H/W258X compound heterozygotes with frank hypouricemia.

rs121907896 (SLC22A12 R90H — Japanese-population allele): A separate rsid (rs121907896) refers to what appears to be the same or an overlapping R90H variant designation found predominantly in East Asian populations in the literature. Population genetics of the SLC22A12 locus differs substantially by ancestry — rs147647315 is the African-enriched GWAS signal, while rs121907896 is the Japan-characterised pathogenic R90H allele. Full haplotype resolution in multi-ancestry datasets has not been published.

rs475688 and rs3825016 (SLC22A12 regulatory and coding variants): These common SLC22A12 variants act in the opposite direction — they increase URAT1 activity and raise serum uric acid. Carriers of the rs147647315 A allele alongside risk alleles at rs475688 or rs3825016 would have competing influences on the URAT1 system; the rare protective allele is expected to dominate at the transporter level, but systemic urate outcomes would depend on other pathway variants (SLC2A9, ABCG2).

The FADS2 gene on chromosome 11 encodes delta-6 desaturase¹¹ delta-6 desaturase
The rate-limiting enzyme that performs the first desaturation step in long-chain PUFA synthesis, converting linoleic acid (LA) to GLA and alpha-linolenic acid (ALA) to stearidonic acid — the upstream gating step before all further elongation and desaturation to EPA, DHA, and arachidonic acid, the rate-limiting enzyme that opens the door to all long-chain polyunsaturated fatty acid synthesis from dietary plant precursors. rs1535 is an intronic FADS2 variant studied in large multi-generational cohorts, and it carries a specific distinction among the FADS2 variants on this platform: it shows consistently stronger associations with PUFA substrate accumulation than the nearby rs174575, and it has been prospectively validated as a pharmacogenomic marker identifying who benefits most from omega-3 supplementation after a heart attack.

The Mechanism

Like rs174575, rs1535 acts through an intronic regulatory mechanism that reduces FADS2 expression and delta-6 desaturase activity. The G allele causes the same fundamental substrate-product inversion seen across the FADS2 locus: precursors linoleic acid (LA) and alpha-linolenic acid (ALA) accumulate while downstream products — gamma-linolenic acid (GLA), arachidonic acid (ARA), EPA, and DHA — are reduced. The effect is additive: each G allele further suppresses delta-6 desaturase function, with GG homozygotes showing the most pronounced phenotype.

The two FADS2 variants rs1535 and rs174575 are in high but incomplete linkage disequilibrium (r² = 0.66, D' = 0.97 in European populations²² r² = 0.66, D' = 0.97 in European populations
Steer et al. Human Molecular Genetics, 2012), meaning they travel together most but not all of the time and can be detected as partially independent signals in large cohorts.

The Evidence

The largest longitudinal evidence comes from the Avon Longitudinal Study of Parents and Children, reported by Steer et al.³³ Steer et al.
Steer CD et al. Polyunsaturated fatty acid levels in blood during pregnancy, at birth and at 7 years: their associations with two common FADS2 polymorphisms. Human Molecular Genetics, 2012 in 4,342 pregnant mothers, 3,343 cord blood samples, and 5,240 children at age 7. Crucially, the authors analyzed both rs1535 and rs174575 in the same sample and found rs1535 had consistently stronger PUFA associations — with approximately 60% larger effect sizes for omega-6 substrates such as linoleic acid. At age 7, the rs1535 G allele showed a negative association with arachidonic acid of β=−0.640 (SE 0.019, p<10⁻⁹) and accounted for approximately 18% of the variance in circulating ARA — a larger explained variance than rs174575 at the same locus.

The clinical implications extend beyond fatty acid levels. The OMEGA-REMODEL randomized trial of high-dose omega-3 fatty acids in 358 post-myocardial infarction patients used rs1535 genotyping as a pharmacogenomic marker. In a post-hoc analysis by Kwong et al.⁴⁴ Kwong et al.
Kwong RY et al. Genetic profiling of fatty acid desaturase polymorphisms identifies patients who may benefit from high-dose omega-3 fatty acids in cardiac remodeling after acute myocardial infarction. PLoS One, 2019 of 312 genotyped patients, GG homozygotes showed dramatically greater benefit from omega-3 supplementation: left ventricular end-systolic volume index improved by −4.4 ml/m² on omega-3 versus +1.2 ml/m² on placebo (p=0.006), an odds ratio of 7.2 for clinically meaningful improvement — compared to an OR of 1.2 in AA carriers. NT-proBNP and galectin-3 (cardiac remodeling biomarkers) were similarly reduced only in GG patients on omega-3.

For lactating mothers, rs1535 has been associated with breast milk PUFA composition in studies of Chinese and Taiwanese women. Ding et al.⁵⁵ Ding et al.
Ding Z et al. Association of polyunsaturated fatty acids in breast milk with fatty acid desaturase gene polymorphisms among Chinese lactating mothers. Prostaglandins Leukot Essent Fatty Acids, 2016 found that minor allele carriers at rs1535 had lower concentrations of GLA and arachidonic acid in breast milk in 209 Chinese women, while Wu et al.⁶⁶ Wu et al.
Wu BH et al. FADS Genetic Variants in Taiwanese Modify Association of DHA Intake and Its Proportions in Human Milk. Nutrients, 2020 demonstrated that accumulated G allele dose at rs1535 was associated with lower breast milk DHA proportions in 164 Taiwanese mothers, with a gene-diet interaction: low-DHA-intake mothers carrying the G allele showed the lowest milk DHA concentrations.

Practical Actions

The core implication of G allele carriage at rs1535 is identical to the broader FADS2 picture: plant-based omega-3 sources (flax, chia, walnuts) supply ALA that cannot efficiently convert to EPA and DHA when delta-6 desaturase is impaired. Preformed EPA and DHA from marine or algae-based sources bypass the blocked first step. The unique addition from rs1535 research is the cardiac intervention signal: GG homozygotes recovering from a myocardial infarction had a 7-fold greater probability of cardiac improvement on high-dose omega-3, which is a level of pharmacogenomic specificity not demonstrated for rs174575 alone.

For lactating mothers with GG genotype, the breast milk DHA deficit creates an additional reason to prioritize preformed DHA supplementation during pregnancy and lactation — not just for their own circulating EPA/DHA status but for the DHA content of milk their infants receive.

Interactions

rs1535 and rs174575 are both intronic FADS2 variants in high LD (r²=0.66) with overlapping but not identical biological signals. Individuals carrying G alleles at both rs1535 and rs174575 have additive impairment of delta-6 desaturase activity. Both variants also interact functionally with the downstream FADS1 delta-5 desaturase variants (rs174547, rs174537): reduced delta-6 output from FADS2 limits the substrate available for FADS1 to act on, compounding the PUFA synthesis deficit when both genes carry risk alleles.

SLC45A2 encodes a melanosomal membrane transporter protein previously known as MATP¹¹ previously known as MATP
membrane-associated transporter protein that regulates melanin synthesis by controlling melanosomal pH through proton transport. The L374F variant (rs16891982) represents one of the most important genetic determinants of pigmentation variation in human populations, with the derived F374 allele nearly fixed in Northern Europeans but rare or absent in African and East Asian populations. This variant exemplifies the evolutionary trade-off²² evolutionary trade-off
lighter skin enhances vitamin D synthesis at high latitudes but reduces photoprotection between adaptive depigmentation for vitamin D synthesis in low-UV environments and protection against UV-induced skin damage.

The Mechanism

The L374F substitution changes a leucine to phenylalanine at position 374 of the SLC45A2 protein. This missense variant alters the protein's ability to maintain optimal melanosomal pH, which is critical for tyrosinase activity—the rate-limiting enzyme in melanin production. The ancestral L374 allele maintains an optimal pH environment for maximal eumelanin (brown-black pigment) synthesis, while the derived F374 allele creates a more acidic melanosomal environment that negatively affects tyrosinase activity³³ negatively affects tyrosinase activity
reduced pH impairs copper binding to tyrosinase, leading to lighter pigmentation. Individuals carrying two copies of the F374 allele produce significantly less melanin, resulting in paler skin, lighter hair, and increased sun sensitivity.

The Evidence

The protective role of the C allele (L374) against melanoma was first identified in a Spanish case-control study of 131 melanoma patients⁴⁴ Spanish case-control study of 131 melanoma patients
OR 0.41, 95% CI 0.24-0.70, P=0.008. This finding has been robustly replicated across multiple populations. A meta-analysis of three South European populations⁵⁵ meta-analysis of three South European populations
1,639 melanoma cases and 1,342 controls confirmed the F374L variant as strongly protective for melanoma (OR 0.41, 95% CI 0.33-0.50, P=3.50×10⁻¹⁷), with the protective effect persisting even after adjustment for clinical confounders. A comprehensive field synopsis and meta-analysis⁶⁶ comprehensive field synopsis and meta-analysis
genome-wide statistical significance P<1×10⁻⁷ identified SLC45A2 at 5p13.2 as one of only four loci with genome-wide significant association with cutaneous melanoma and strong epidemiological credibility.

Conversely, the ancestral L374 allele (C) is strongly associated with dark pigmentation. In a European population study⁷⁷ European population study
OR 7.05 for black hair, the L374 allele significantly increased the likelihood of having black hair color. A Spanish population analysis of 558 individuals⁸⁸ Spanish population analysis of 558 individuals
statistically significant correlation P<0.001 revealed that L374F allele frequency correlated with incident UV radiation intensity, with the 374F allele more frequent in lighter-skinned individuals and showing evidence of positive selection in European populations.

The F374 allele shows extreme population differentiation, with frequencies of approximately 96.5% in Germans, 88-94% in Southern Europeans, 61.5% in Turks, but only 14.7% in South Asians and 5.9% in Bangladeshis, and rare in sub-Saharan African populations⁹⁹ rare in sub-Saharan African populations
~14% frequency and essentially absent in East Asians. This distribution pattern indicates recent positive selection¹⁰¹⁰ recent positive selection
evidence from haplotype analysis and neutrality tests favoring lighter pigmentation in European populations over the past 5,000-20,000 years.

Practical Implications

Your genotype at this position directly influences your skin's natural photoprotection capacity and melanoma risk. The paradox is straightforward: lighter skin (GG or CG genotypes) enhances vitamin D synthesis but dramatically increases vulnerability to UV-induced DNA damage and melanoma. Individuals with one or two copies of the G allele require more rigorous photoprotection than those with the CC genotype.

For GG and CG carriers, sun protection is not optional—it is a medical necessity. Use broad-spectrum sunscreen SPF 30 or higher daily on all exposed skin, reapplied every 2 hours during sun exposure. Seek shade between 10 AM and 4 PM when UV intensity peaks. Wear protective clothing including long sleeves, wide-brimmed hats, and UV-blocking sunglasses. Avoid tanning beds entirely, as they deliver concentrated UV radiation without the photoprotective adaptations that occur with gradual sun exposure.

Annual full-body skin examinations by a dermatologist are recommended for GG carriers, particularly those with additional risk factors such as fair hair, multiple nevi (moles), or a family history of melanoma. Self-examination monthly can detect suspicious lesions early—melanoma detected at stage I has a 99% five-year survival rate.

For individuals with darker constitutive pigmentation (CC genotype), melanoma risk is substantially lower but not zero. While daily sunscreen may not be medically necessary in the same way, sun protection during prolonged outdoor activities and awareness of melanoma warning signs remain important.

Interactions

SLC45A2 L374F interacts epistatically with variants in other pigmentation genes to modulate melanoma risk. The most significant interaction occurs with MC1R (melanocortin-1 receptor) variants. Individuals carrying two or more MC1R red hair color variants¹¹¹¹ Individuals carrying two or more MC1R red hair color variants
well-established high-risk genotypes have decreased melanoma risk if they concurrently carry the protective SLC45A2 L374 variant. This suggests that while MC1R variants increase melanoma susceptibility through impaired tanning response, the high melanin synthesis enabled by the ancestral L374 allele can partially offset this risk.

Additional interactions have been documented with OCA2, ASIP, TYR, and TYRP1 variants. A large Australian case-control study¹²¹² large Australian case-control study
1,738 cases and 4,517 controls detected significant epistatic interactions between SLC45A2 and OCA2 alleles, and between MC1R and ASIP alleles, in modulating melanoma risk. These pigmentation loci together account for approximately 12% of familial melanoma risk in high-UV populations.

The combined effect of multiple light-pigmentation variants compounds melanoma susceptibility beyond simple additive models. Individuals carrying high-risk alleles at SLC45A2, MC1R, TYR, and OCA2 simultaneously should be considered at substantially elevated risk and prioritized for intensive photoprotection counseling and surveillance.

The CYP11B2 gene¹¹ CYP11B2 gene
encodes aldosterone synthase, the enzyme catalyzing the final three steps of aldosterone biosynthesis in the adrenal cortex. Aldosterone is the body's primary mineralocorticoid hormone — it controls sodium retention, potassium excretion, and blood pressure by acting on the kidneys' collecting ducts. The rs1799998 variant (-344C>T) sits in the promoter region of CYP11B2 at a binding site for steroidogenic factor-1 (SF-1)²² steroidogenic factor-1 (SF-1)
a transcription factor that drives expression of steroid-synthesizing enzymes including CYP11B2. Depending on which allele you carry, your adrenal glands may be genetically primed to produce more aldosterone throughout your life.

Important note on allele notation: Published literature uses coding-strand notation (C and T alleles). Because CYP11B2 is on the minus strand, genome files report the complementary plus-strand alleles: A corresponds to the T allele described in papers (the higher-expression allele), and G corresponds to the C allele. All genotypes in this profile use plus-strand notation.

The Mechanism

The -344 position in the CYP11B2 promoter sits within the SF-1 binding site³³ SF-1 binding site
SF-1, encoded by NR5A1, is a master regulator of adrenal steroidogenic gene expression. The T allele (A on plus strand) alters the binding affinity of this site, shifting the regulatory landscape toward enhanced transcriptional output.

CYP11B2 exists within a haplotype block containing three linked promoter variants. The haplotype containing -344T (haplotype-I) shows measurably greater CYP11B2 expression — demonstrated in transgenic mice carrying the human gene with haplotype-I, which produced 2.2-fold higher mRNA in adrenals and 1.54-fold higher expression in kidneys compared to haplotype-II (-344C) mice. Critically, haplotype-I mice developed a 7 mmHg higher baseline blood pressure, and under high-salt diet, failed to appropriately suppress aldosterone — driving further blood pressure elevation — while haplotype-II mice showed normal salt-induced RAAS suppression.

The Evidence

In a multi-ethnic study of 1,313 participants, the TT genotype was associated with 14% higher plasma aldosterone levels and 3.7 mmHg higher systolic / 2.1 mmHg higher diastolic blood pressure compared to CC carriers⁴⁴ the TT genotype was associated with 14% higher plasma aldosterone levels and 3.7 mmHg higher systolic / 2.1 mmHg higher diastolic blood pressure compared to CC carriers, after adjustment for age, sex, and ethnicity. The T allele was also over-represented in individuals with elevated aldosterone-to-renin ratios.

In an Egyptian cohort, the T allele was significantly more frequent in hypertensive patients (OR 2.51; 95% CI 1.3–3.5; P=0.002)⁵⁵ the T allele was significantly more frequent in hypertensive patients (OR 2.51; 95% CI 1.3–3.5; P=0.002). The TT genotype was specifically associated with greater left ventricular mass index (LVMI), suggesting that the elevated aldosterone drives not just blood pressure but also cardiac remodeling.

For cardiac structure, the -344 C/T polymorphism is associated with left ventricular structure in arterial hypertension⁶⁶ the -344 C/T polymorphism is associated with left ventricular structure in arterial hypertension, with different patterns by genotype: CC carriers tend toward eccentric LVH, while a strong correlation between LV mass and urinary sodium excretion was observed specifically in CC and intron-2-conversion carriers⁷⁷ CC and intron-2-conversion carriers, suggesting the sodium-LV mass link operates through different mechanisms by genotype.

The SILVHIA trial found a striking pharmacogenomic signal: TT carriers showed -21 mmHg systolic BP reduction with irbesartan, versus 0 mmHg for CC carriers⁸⁸ TT carriers showed -21 mmHg systolic BP reduction with irbesartan, versus 0 mmHg for CC carriers, suggesting the T allele's excess aldosterone production creates greater suppressibility by AT1 receptor blockade. A Chinese study found CC+CT carriers responded better to valsartan (4.7 mmHg greater SBP reduction), illustrating that drug-response findings vary by population.

One large multi-ethnic U.S. study (n=3,452) found no association with blood pressure, plasma aldosterone, or LV mass⁹⁹ found no association with blood pressure, plasma aldosterone, or LV mass, highlighting genuine heterogeneity in the literature — likely driven by differences in dietary sodium, comorbidities, population genetic backgrounds, and LD patterns.

Practical Actions

The most actionable implication of the -344T/A genotype is salt sensitivity of blood pressure. Even without confirmed hypertension, carriers of one or two A alleles (particularly AA homozygotes) have a biological predisposition toward aldosterone-mediated sodium retention. Reducing dietary sodium blunts the aldosterone-driven pathway at its source.

If you have hypertension and carry the AA genotype, AT1 receptor blockers (irbesartan, valsartan) may offer superior blood pressure reduction by blocking the downstream effects of elevated aldosterone. Discuss this pharmacogenomic data with your physician when selecting antihypertensive therapy.

Interactions

CYP11B2 rs1799998 functions within the renin-angiotensin-aldosterone system (RAAS) pathway alongside AGTR1 rs5186 (A1166C), which affects angiotensin II receptor expression, and AGT rs699 (M268T), which influences angiotensinogen levels. Published studies have found interactive effects between CYP11B2 -344T and ACE insertion/deletion on atrial fibrillation risk and T2DM susceptibility. Individuals carrying multiple RAAS-sensitizing variants across CYP11B2, AGTR1, and AGT may have additive blood pressure effects beyond any single variant, with the CYP11B2 AA + AGTR1 CC combination representing the highest sodium-sensitive hypertension burden within this pathway.

Von Willebrand factor¹¹ Von Willebrand factor
a large multimeric glycoprotein produced by endothelial cells and megakaryocytes; acts as the primary platelet adhesion bridge at sites of vascular injury and as the plasma carrier that protects coagulation factor VIII from premature degradation is arguably the single most important quantitative determinant of bleeding and thrombosis risk below the level of frank coagulation factor deficiency. Normal-range plasma VWF antigen levels span roughly 50–200 IU/dL — a four-fold window — and that variation is substantially heritable. The rs1800380 variant falls within a 50-kilobase stretch of the VWF gene that has the strongest known cis-acting influence on circulating VWF concentrations in people of European and African descent.

The Mechanism

rs1800380 is a synonymous C>T substitution in VWF exon 22 (c.2880G>A; NM_000552.5) that does not change the encoded amino acid — both the C and T alleles produce arginine at codon 960. The T allele is on the GRCh38 plus strand; the VWF gene is on the minus strand, so this corresponds to a c.2880G>A coding-strand change (G→A) that is silent at the protein level. Yet the variant strongly associates with plasma VWF antigen levels across independent populations.

The likely explanation is that rs1800380 itself is not the causative change but rather a tag SNP²² tag SNP
a variant in strong linkage disequilibrium with the true functional variant, allowing it to serve as a reliable proxy for the causal haplotype in GWAS. It sits within haplotype block 5³³ haplotype block 5
a 50-kb stretch of the VWF gene encoding the D2, D', and D3 domains that regulate VWF multimerization, packaging into Weibel-Palade bodies, and regulated secretion into the circulation. The T allele marks the high-VWF haplotype in this block. The causal variant — likely within the same block — may alter VWF mRNA secondary structure, splicing efficiency, transcription factor binding, or protein folding in the secretory pathway.

The effect of the T allele is additive: each copy adds approximately +0.03 units (log-scale) to circulating VWF:Ag after adjustment for ABO blood group, and the p-value for this association is 4.4×10⁻⁹ post-ABO adjustment in the ARIC cohort (n=7,856). This level of evidence is genome-wide significant and replicates across European and African-descent populations.

The Evidence

The definitive mapping of rs1800380 to VWF antigen levels comes from the ARIC cohort target-gene analysis⁴⁴ ARIC cohort target-gene analysis
Campos et al. Blood 2011, 7,856 European-descent subjects, 78 VWF SNPs analyzed. Of 18 SNPs significantly associated with VWF:Ag in this dataset, rs1800380 was one of only two in actual exonic positions (the other being rs1063857 in exon 18). The pre-ABO p-value was 1.6×10⁻⁷; after ABO adjustment the signal strengthened to 4.4×10⁻⁹, confirming that the haplotype's VWF-raising effect is mechanistically independent of blood-group-mediated VWF clearance. The 15 significant block-5 and block-6 SNPs form two distinct haplotypes that together explain a substantially larger fraction of within-gene VWF level variance than any single SNP alone.

The downstream clinical consequence of elevated VWF is well established. A transethnic GWAS meta-analysis by Sabater-Lleal et al. 2019⁵⁵ Sabater-Lleal et al. 2019 used Mendelian randomization to demonstrate a causal relationship between plasma VWF levels and ischemic stroke risk — meaning that genetically elevated VWF is not merely a marker of vascular inflammation but a driver of thrombotic events. This finding upgrades the clinical relevance of VWF-raising variants from "associated with higher biomarker" to "causally linked to stroke," at least at the population level.

Plasma VWF levels above 150 IU/dL are associated with 2–3× increased risk of venous thromboembolism in longitudinal studies (Vischer 2011)⁶⁶ (Vischer 2011). The VWF-raising haplotype tagged by rs1800380 T shifts baseline VWF in the direction of this elevated-risk zone, particularly in non-O blood group individuals (who already have slower VWF clearance due to O-type glycan differences).

In the Rotterdam Study's promoter analysis (de Lange et al. 2004)⁷⁷ (de Lange et al. 2004), a promoter haplotype associated with higher VWF levels showed a 2.6-fold increased coronary heart disease risk in subjects with advanced atherosclerosis — illustrating how the VWF-raising effect becomes most clinically relevant in the setting of other vascular risk factors.

The evidence level is strong: the rs1800380 T allele association with VWF:Ag levels reaches genome-wide significance, replicates across ancestries, and the downstream cardiovascular consequences of elevated VWF have causal support from Mendelian randomization. The individual effect size is modest (explaining <1% of VWF variance on its own), and the haplotype context means the variant's specific contribution cannot be fully disentangled from neighboring SNPs without fine-mapping.

Practical Actions

For TT homozygotes carrying two copies of the high-VWF haplotype tag, the priority is knowing whether your circulating VWF:Ag is actually elevated — only a blood test can confirm this. Levels persistently above 150 IU/dL (particularly in non-O blood group individuals) warrant proactive monitoring and risk factor management. The pro-thrombotic risk is most relevant in specific, high-stakes contexts: prolonged immobility, major surgery, use of estrogen-containing contraceptives, or concurrent inherited thrombophilia.

CT heterozygotes have intermediate VWF levels and a proportionally intermediate risk profile; measurement is useful if other thrombotic risk factors are present.

CC homozygotes carry the lower-VWF haplotype and have no elevation-specific action items; their VWF levels are in the population-normal to low-normal range for this variant.

Interactions

ABO blood group is the dominant modifier of plasma VWF levels in all populations, accounting for ~15% of VWF antigen variance via glycan-mediated differences in clearance rate. Non-O individuals with the T allele haplotype will show the largest VWF elevations — the high-expression haplotype (tagged by T) combined with non-O blood group (slower VWF clearance) acts in the same direction, compounding VWF elevation above either factor alone.

Among VWF coding variants, rs216311 (Thr1381Ala, exon 28) independently raises VWF levels through a structural mechanism in the D4 domain. Carriers of both the rs1800380 T haplotype and the rs216311 C allele (Ala) will have the highest within-gene VWF levels. The ADAMTS13 substrate-cleavage variants in this category (rs28647808, rs2288904) operate through a complementary VWF-processing pathway: reduced ADAMTS13-mediated VWF cleavage amplifies whatever VWF is being secreted, so high secretion (rs1800380 T haplotype) combined with reduced cleavage (ADAMTS13 variants) further elevates ultra-large VWF multimers.

The HFE gene encodes the hereditary hemochromatosis protein¹¹ hereditary hemochromatosis protein
A membrane protein structurally similar to MHC class I molecules that regulates iron absorption by sensing blood iron levels and modulating hepcidin expression, a key regulator of iron homeostasis. A single G-to-A change at nucleotide 845 replaces cysteine with tyrosine at position 282 of the protein, destroying a critical disulfide bond in the alpha-3 domain²² alpha-3 domain
The immunoglobulin-like C1-set domain that mediates binding to beta-2 microglobulin, essential for proper protein folding and cell surface expression. This variant — universally known as C282Y — is the primary cause of hereditary hemochromatosis type 1, the most common autosomal recessive condition in people of European descent.

The Mechanism

HFE normally forms a complex with beta-2 microglobulin³³ beta-2 microglobulin
A small protein that stabilizes MHC class I and class I-like molecules, enabling their transport to the cell surface and travels to the cell surface, where it interacts with transferrin receptors (TfR1 and TfR2) to sense circulating iron levels. When iron is sufficient, this signaling cascade stimulates the liver to produce hepcidin⁴⁴ hepcidin
The master iron-regulatory hormone; it blocks ferroportin, the only known cellular iron exporter, thereby reducing iron absorption from the gut and iron release from macrophages, which in turn blocks iron absorption from the intestine by degrading ferroportin⁵⁵ ferroportin
The sole known iron export channel on intestinal epithelial cells and macrophages on gut cells.

The C282Y mutation prevents HFE from binding beta-2 microglobulin. Without this partner, the protein cannot fold correctly, never reaches the cell surface, and accumulates uselessly inside the cell. The result is a broken iron sensor: the liver produces inappropriately low hepcidin regardless of how much iron is already in the body. With the brake removed, the gut absorbs 2-3 times more dietary iron than normal, and macrophages release stored iron unchecked. Over decades, this excess iron deposits in the liver, heart, pancreas, and joints.

The Evidence

The landmark 1996 discovery⁶⁶ landmark 1996 discovery
Feder JN et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet, 1996 by Feder and colleagues identified the HFE gene and found C282Y homozygosity in 83% of hereditary hemochromatosis patients. This remains the most common genetic cause of iron overload worldwide.

The Melbourne Collaborative Cohort Study⁷⁷ Melbourne Collaborative Cohort Study
Allen KJ et al. Iron-overload-related disease in HFE hereditary hemochromatosis. N Engl J Med, 2008 followed 31,192 persons of European descent for 12 years. Among 203 C282Y homozygotes, iron-overload-related disease developed in 28.4% of men but only 1.2% of women — highlighting the dramatic sex difference in clinical penetrance. Men are far more vulnerable because they lack the protective iron losses from menstruation.

A UK Biobank analysis⁸⁸ UK Biobank analysis
Pilling LC et al. Common conditions associated with hereditary haemochromatosis genetic variants: cohort study in UK Biobank. BMJ, 2019 of 451,243 participants confirmed that C282Y homozygous men have significantly higher rates of liver disease (HR 2.22), diabetes (HR 1.72), and arthritis compared with non-carriers. Hemochromatosis was diagnosed in 21.7% of homozygous men by end of follow-up.

A meta-analysis of 43 study populations⁹⁹ meta-analysis of 43 study populations
Bacon BR et al. Hemochromatosis genotypes and risk of iron overload — a meta-analysis. Genet Med, 2011 pooling 9,986 cases and 25,492 controls established C282Y homozygosity as the overwhelmingly dominant genetic risk factor for both biochemical and clinical iron overload.

Practical Implications

For AA (C282Y homozygous) individuals: you carry the highest-risk genotype for hereditary hemochromatosis. Regular serum ferritin and transferrin saturation monitoring is essential. If iron levels are elevated, therapeutic phlebotomy (regular blood removal) is the standard treatment and is highly effective when started before organ damage occurs. Limit iron-fortified foods and high-dose vitamin C supplements, which enhance iron absorption. Avoid excess red meat and iron-containing multivitamins.

For AG (heterozygous carrier) individuals: you carry one copy of C282Y. Your iron levels may run slightly higher than average, which is generally benign and may even protect against iron deficiency anemia. Routine ferritin screening every few years is reasonable. Significant iron overload from heterozygosity alone is rare.

For GG (wild-type) individuals: you have normal HFE function at this locus. Standard dietary iron recommendations apply.

Interactions

The most clinically significant interaction is with H63D (rs1799945)¹⁰¹⁰ H63D (rs1799945)
HFE H63D is a milder variant in the same gene; compound heterozygosity (one C282Y + one H63D) confers a small risk of mild iron overload in the same gene. Compound heterozygosity — carrying one C282Y allele and one H63D allele — produces a mildly elevated risk of iron overload, though far less than C282Y homozygosity. A study of compound heterozygotes¹¹¹¹ study of compound heterozygotes
Walsh A et al. HFE C282Y/H63D compound heterozygotes are at low risk of hemochromatosis-related morbidity. Hepatology, 2009 found that documented iron-overload-related disease occurred in only about 1-2% of C282Y/H63D compound heterozygotes, similar to wild-type rates. However, mean serum ferritin and transferrin saturation were significantly elevated compared with non-carriers, so monitoring remains reasonable.

If a user carries C282Y heterozygous (AG at rs1800562) plus H63D heterozygous (CG at rs1799945), a compound implication should advise periodic ferritin monitoring, as the combination slightly amplifies iron absorption beyond either variant alone. This interaction is well-documented but low-penetrance.

The TNF gene encodes tumor necrosis factor-alpha¹¹ tumor necrosis factor-alpha
a master regulator of inflammation and immune response, produced by macrophages, T cells, and other immune cells. This -308 G>A variant sits in the promoter region²² promoter region
the DNA sequence that controls how much TNF-alpha gets made of the gene on chromosome 6p21.3, within the major histocompatibility complex. The A allele disrupts transcription factor binding sites and increases TNF-alpha production approximately 2-fold compared to the G allele when immune cells are stimulated.

The Mechanism

This is a regulatory variant that affects gene transcription³³ affects gene transcription
how much protein gets made from the gene. The -308 position is 308 base pairs upstream of where the TNF gene starts being copied into RNA. The A allele alters binding sites for nuclear transcription factors, leading to enhanced transcriptional activity in immune cells. When your immune system encounters a threat, carriers of the A allele produce substantially more TNF-alpha than GG carriers, amplifying the inflammatory response.

The Evidence

A meta-analysis of 1,774 controls and 1,147 celiac disease cases found the A allele confers a 2-fold increased risk (OR 2.051) , with

AA homozygotes showing 6.6-fold increased risk (OR 6.626) .

The A allele leads to approximately 2-fold higher TNF-alpha transcription upon immune cell stimulation , and carriers show significantly higher serum TNF-alpha levels .

The variant also predicts response to anti-TNF biologic drugs⁴⁴ anti-TNF biologic drugs
medications like infliximab and etanercept that block TNF-alpha used to treat rheumatoid arthritis and inflammatory bowel disease.

RA patients carrying the GG genotype are better responders to etanercept, while the AA genotype significantly decreases response .

The same pattern holds for etanercept—GG shows better response than AA or AG .

Associations have been reported with multiple autoimmune conditions.

In rheumatoid arthritis patients, A allele carriers show higher risk of cardiovascular events (HR 1.72), particularly in those also carrying the rheumatoid shared epitope . Studies link the variant to increased risk of vitiligo, preeclampsia in Asian and Caucasian populations, and aggressive periodontitis.

Practical Implications

If you have autoimmune disease, particularly rheumatoid arthritis or inflammatory bowel disease, your -308 genotype may influence how well you respond to anti-TNF biologic medications. GG carriers tend to respond better to anti-TNF drugs like etanercept (Enbrel), while A allele carriers may need alternative mechanisms. If you're an A allele carrier who doesn't respond well to one anti-TNF drug, switching to a different mechanism of action (like IL-6 inhibitors or JAK inhibitors) may be more effective than trying another anti-TNF.

For those with one or two A alleles, the A allele doesn't cause inflammation by itself—it amplifies your body's inflammatory response when triggered. This means known inflammatory triggers may provoke stronger responses in A allele carriers, and autoimmune flares may be more intense.

Interactions

The TNF-308 variant sits within a cluster of related TNF polymorphisms including rs361525⁵⁵ rs361525
TNF-238 G>A, another promoter variant and rs1799724⁶⁶ rs1799724
TNF-857 C>T. These variants are in linkage disequilibrium, meaning they're often inherited together. Compound effects with other inflammatory pathway genes (IL-6, IL-10, IL-1) have been documented, particularly for predicting anti-TNF drug response.